Angiopoietin-1 is a vascular strengthening factor during vascular development and a protective factor for pathological vascular inflammation and leakage. Brain vascular leaking and inflammation are two important pathological processes of stroke; therefore, we hypothesized that variants of the microRNA-binding site in angiopoietin-1 would affect its expression and confer a risk of stroke. To test our hypothesis, a predicted microRNA-binding site was found in the 3 ′ -UTR of angiopoietin-1 using bioinformatics; variant rs2507800 was identified to be located in the miR-211-binding site of angiopoietin-1. Secondly, the effects of the identified variant on angiopoietin-1 translation were assessed using a luciferase reporter assay and ELISA. We found that the A allele of rs2507800 suppressed angiopoietin-1 translation by facilitating miR-211 binding, but not the T allele. Subjects carrying the TT genotype had higher plasma angiopoietin-1 levels than those with the A allele. Finally, the association of the variant with stroke was tested in 438 stroke patients and 890 controls, and replicated in an independent population of 1791 stroke patients and 1843 controls. The TT genotype resulted in a significant reduction in overall stroke risk {OR, 0.51 [95% confidence interval (CI), 0.36 -0.74], P 5 0.0003}, ischemic stroke [OR, 0.56 (95% CI,), P 5 0.007] and hemorrhagic stroke [OR, 0.46 (95% CI, 0.26 -0.80), P 5 0.007]. These results were confirmed in an independent study. Our results provide evidence that the TT genotype (rs2507800) in the 3 ′ -UTR of angiopoietin-1 might reduce the risk of stroke by interfering with miR-211 binding.
INTRODUCTION
Stroke is the second most common cause of death worldwide, is a major cause of long-term disability and has a great impact on public health. Each year in China, 2.5 million people have strokes, and .1 million die from stroke-related causes; .7 million patients have survived strokes but are disabled as a result (1) . Stroke risk factors include increased age, hypertension, cigarette smoking, alcohol abuse, diabetes mellitus (DM), hypercholesterolemia and a history of coronary heart disease (2) . However, these risk factors account for 50% of the risk of stroke, implying that other factors, including genetics, might be involved in stroke risk (3) . In fact, twin and familial aggregation studies suggest that the risk of stroke has a substantial genetic component (4 -6) . Identification of susceptibility genes for stroke is expected to elucidate new pathophysiological mechanisms of the disease and lead to the development of novel preventive measures. In addition, the ratio of stroke over coronary heart disease is 4-5 to 1 in China, which is in sharp contrast to western countries (1 -2) . This observation also indicates that genetics might contribute to the different ratio of stroke and coronary heart disease between Chinese and westerners. Recently, several candidate genes have been linked to stroke susceptibility † J.C. and T.Y. contributed equally to this work. * To whom correspondence should be addressed at: FuWai Hospital, Chinese Academy of Medical Sciences, 167 Beilishilu, Beijing 100037, China. Tel: +86 1068333902; Fax: +86 1068331730; Email: huirutai@sglab.org through genome-wide association studies (GWASs); however, the contribution of genetic risk to stroke, especially hemorrhagic stroke, is still incompletely understood (7) .
Angiopoietin-1 is a ligand of Tie2, the endothelial-specific tyrosine kinase receptor and an essential mediator of angiogenesis (8 -10) . Angiopoietin-1 is also an endothelial survival factor (11) and has been shown to inhibit endothelial permeability in vitro and to protect blood vessels from leaking in vivo (12) (13) (14) . In addition, angiopoietin-1 blocks leukocyte adhesion to the vascular endothelium and inhibits the expression of tissue factors and various adhesion molecules stimulated by inflammatory cytokines in endothelial cells (ECs) (12, (15) (16) (17) . These findings strongly support the view that angiopoietin-1 is an angiogenic growth factor with antipermeability and anti-inflammatory properties. Chronic or uncontrolled inflammation plays an important role in many diseases (18) , including stroke (19) .
On the basis of aforementioned findings, we speculated that variants able to interrupt angiopoietin-1 expression would modify the genetic susceptibility to stroke. MicroRNAs (miRNAs) are endogenously expressed RNAs of 18-24 nucleotides in length, which regulate gene expression through translational repression by binding to complementary, or partially complementary, target messenger RNAs (mRNAs) and targeting the mRNA for degradation or translational inhibition (20) . In mammals, specific miRNAs are known to control biological processes such as development, neuronal cell fate, apoptosis, proliferation, adipocyte differentiation, hematopoiesis and exocytosis (21) , as well as the clinical courses of diseases such as cancer (22, 23) and stroke (24) .
The efficiency of binding of miRNAs to target transcripts depends on the sequence as well as the intramolecular structure of the transcript. Single nucleotide polymorphisms (SNPs) can result in alterations in the structure of regions flanking them, thereby influencing the accessibility for miRNA binding and expression of the target gene (25) and affecting the risk of common diseases. Indeed, several polymorphisms in miRNA-binding sites have been reported to influence the expression of the target gene and to be associated with risk of common diseases. For example, the variant rs12720208 in the miRNA-433-binding site of FGF20 has been shown to increase translation of FGF20 and confer risk for Parkinson disease (26) . The variant rs5186 in the miRNA-155-binding site of AGTR1 has been shown to decrease translation of AGTR1 at allele A, but not at allele C (27, 28) ; the latter allele has been associated with hypertension (29, 30) .
Through a bioinformatics approach, we identified a variant, rs2507800, located in the miRNA-211 (miR-211) target site in the 3 ′ untranslated region (3 ′ -UTR) of angiopoietin-1. These data led us to hypothesize that variant rs2507800 could modify miR-211 binding to angiopietin-1 and contribute to the genetic susceptibility to stroke.
RESULTS

Variant rs2507800 A/T of angiopoietin-1 is in the miR-211-binding site
The variant rs2507800 is an A to T change (mRNA sequence as reference) and a computer alignment demonstrated that this polymorphism occurs in the complementary binding sequence of miR-211 (Fig. 1) .
The T-allele of angiopoietin-1 rs2507800 is resistant to miR-211-induced downregulation of angiopoietin-1
We cloned a 48 bp sequence, comprising the predicted binding sequence around rs2507800, into the 3 ′ -UTR of a luciferase reporter vector, pMIR-REPORT TM , carrying the wild-type (pMIR-A, with the A allele) and mutant (pMIR-T, with the T allele) sequence of rs2507800, respectively. A549 cells were co-transfected with these reporter constructs and with a PremiR miRNA, a precursor of miR-211, or with a PremiR as a negative control. The pMIR-A reporter/PremiR-miRNA showed a significant reduction of pMIR-A signal (56% of the negative control; P ¼ 0.0001) (Fig. 2) . On the other hand, no significant difference was found in luminescence signal between pMIR-T reporter/PremiR miRNA and controls (P ¼ 0.61).
To explore the effects of miR-211 on angiopoietin-1 translation in vivo, plasma concentrations of angiopoietin-1 were determined in 119 subjects randomly selected from controls in the first study. Among them, rs2507800 T allele carriers had a significant increase in the level of angiopoietin-1 compared with A allele carriers (P ¼ 0.027, Kruskal -Wallis test). Plasma angiopoietin-1 levels were higher in subjects with the TT genotype (n ¼ 22, 8.58 ng/ml, 25th-75th percentiles, 6.94-18.98 ng/ml) than in those with the AT genotype (n ¼ 59, 7.11 ng/ml, 25th-75th percentiles, 5.75-13.00 ng/ml, P ¼ 0.023) or the AA genotype (n ¼ 38, 7.33 ng/l, 25th-75th percentiles, 5.29-10.57 ng/ml, P ¼ 0.014) (Fig. 3) . These results were consistent with the in vitro luciferase activity study.
Clinical characteristics
To test the hypothesis that the variant rs2507800 would modify stroke susceptibility, we investigated the association of variant rs2507800 with stroke in two case -control studies. The clinical characteristics of patients and controls are shown in Tables 1 and 2 , respectively. As expected, cases had higher prevalences of conventional cardiovascular risk factors, including cigarette smoking, history of hyper- tension and higher blood pressure, higher triglycerides and lower HDL-cholesterol than the controls.
The T-allele of variant rs2507800 is possibly associated with stroke risk
The distribution of variant rs2507800 is shown in Tables 3 and 4 for the two populations, and conformed to Hardy-Weinberg ], compared with the AT and AA genotypes. The estimated population-attributable fraction in strokes overall for rs2507800TT was 6%; in lacunar infarction it was 9% and in hemorrhagic stroke it was 11%. 
DISCUSSION
In this study, we found that the T allele of variant rs2507800 in angiopoietin-1 was resistant to miR-211-induced downregulation of angiopoietin-1, and might negatively associate with stroke risk. The possible association is independent of conventional vascular risk factors. Population stratification might lead to a spurious association. However, in the present study, all subjects are of Han nationality, and the distribution of the genotypes is in agreement with the HWE in both patients and controls. In the Han Chinese, geographic matching is a good proxy for genetic matching, with the exception of the metropolitan cities, where geographical location is no longer a good indicator of ancestral origin (31) . In the first study, both cases and controls were from the same community (Pingqiao) in Xinyang city (not a metropolitan city). In the second study, the population stratification was minimized by genotyping microsatellite markers randomly selected from whole-genome regions, irrelevant to stroke in patients and in controls, and no association was identified between these markers and stroke (32) . Although these strategies were taken to minimize the population stratification, we are still not sure that the population stratification was completely ruled out since the best strategies for ruling out population stratification, such as family-based study and correction with principal components of ancestry determined using a very dense genotype data set (33,34), were not included in these strategies. This is one of the limitations of the present study. It is well known that a false-positive result due to statistical fluctuation is common in a case -control study; to minimize this possibility, we replicated the initial association in the second independent population and tested the association in the two studies combined. The consistent results support the association probably being a real one.
Recently, several GWASs for stroke have been reported (35-39), but they did not detect the association of rs2507800 in angiopoietin-1 with stroke. The variant rs2507800 was registered in the HapMap database, but the exact genotype data are not available from the NCBI database. The minor allele frequency (MAF) of rs2507800 was 0.470 for CEPH, 0.420 for Caucasian, 0.370 for JPT and 0.320 for African American. In the present study, the MAF of rs2507800 was 0.409 for Han Chinese in Beijing. These data imply that the variant rs2507800 might have different effects on stroke (or other biological and pathological processes) among different populations; however, none of the GWASs for stroke was reported in Chinese populations. In addition, the current GWAS platforms do not contain rs2507800, even in the Affymetrix Genome-Wide Human SNP Array 6.0 or Illumina Human1M-Duo BeadChip. Therefore, the current GWASs using commercial chips cannot detect the association of rs2507800 in angiopoietin-1 with stroke directly. On the other hand, this variant might have been detectable in other GWASs for stroke through a variant with linkage disequlibrium to rs2507800; however, none of those previous GWASs for stroke showed that any variant in the angiopoietin-1 region was associated with stroke, indicating that the variant rs2507800 is a novel genetic risk factor of stroke. In fact, stroke is a complex disease; it is difficult to elucidate all the genetic risk factor using a few GWASs, although GWAS is a powerful tool in the field of complex disease study. Indeed, the results from different GWASs for stroke are not identical, even though they are from the same nationality (35, 37) .
The control of vascular homeostasis is mediated through the maintenance of EC monolayer integrity, which is responsible for the tonic impermeable nature of blood vessels. Altered endothelial integrity underlies the changes in vascular permeability, as seen in inflammatory responses and angiogenesis, and in diseases such as rheumatoid arthritis, atherosclerosis and stroke (40) . During ischemic stroke and subsequent reperfusion, the tight junctions of the bloodbrain barrier (BBB) are disrupted, resulting in an increase in vascular-derived substances entering the brain (41) . The most significant risk factor for intracerebral hemorrhage (ICH) is hypertension, which is found in up to 89% of patients with hemorrhage. Chronic hypertension induces welldescribed changes in arteries and arterioles, similar to that seen in SHRsp rats, including smooth muscle cell disarray, structural remodeling (42, 43) and BBB breakdown (44) . A recent study showed that vascular permeability starts to increase 2 weeks before ICH in salt-loaded SHRsp rats (45) .
One important cellular function of angiopoietin-1 is to improve the integrity of the endothelial monolayer. Angiopoietin-1 has been reported to suppress the permeability of the monolayer in cultured human umbilical artery ECs (HUVECs), and glomerular ECs, augment the integrity of unstimulated monolayers and counteract the increased permeability due to EC activation following stimulation of thrombin, VEGF or TNFa (12, 46) . In addition, angiopoietin-1 reduces vascular leakage in the brain following experimental embolic cerebral occlusion in mice (47) . In a mouse model of stroke, angiopoietin-1 inhibits vascular leaking and decreases the lesion size (48) . Angiopoietin-1 has also been found to reduce brain endothelial permeability via upregulation of ZO-1 and ZO-2 (49, 50) . These findings support the view that upregulation of angiopoietin-1 could maintain the integrity of the EC monolayer and the stability of tight junctions. The TT genotype (rs2507800) is resistant to miR-211-induced downregulation of angiopoietin-1, resulting in higher plasma levels of angiopoietin-1 than in the other genotypes. These effects could be translated into a reduction of stroke risk. The present results were consistent with our previous study, which showed that SNPs in angiopoietin-2 and KDR, both of which are mediators of vascular leakage, are associated with the risk of stroke (51, 52) .
Inflammatory processes have increasingly been shown to be involved in the pathogenesis of cerebrovascular diseases, including ischemic stroke and ICH. The other important function of angiopoietin-1 is its ability to inhibit vascular inflammation, by suppressing adhesion of leukocytes to VEGF-stimulated HUVEC (15) through inhibiting the expression of a number of inflammation-associated adhesion molecules. Specifically, the expression of E-selectin, intercellular adhesion molecule-1 (ICAM1) and vascular cell adhesion molecule-1 (VCAM1) has been reported to be decreased by angiopoietin-1 in VEGF-activated HUVECs (12, 15) . In addition, angiopoietin-1 blocks TNFa and VEGF-induced tissue factor expression in HUVECs (16) . These findings also support the hypothesis that upregulation of angiopoietin-1 in the TT genotype could result in suppression of vascular inflammation and, consequently, a reduction of stroke risk. Our results are consistent with several previous association studies between variants in inflammation-related genes and risk of stroke. For example, the -572G/C polymorphism of the interleukin-6 (IL-6) gene has been associated with risk of both atherothrombotic cerebral infarction and ICH (53) . The -511C/T IL-1beta polymorphism has been associated with a decreased risk of stroke (54) . Another association study found that the C804A polymorphism in lymphotoxinalpha (LTA) is a risk factor for stroke (55) . These results suggest that polymorphisms of inflammation-related genes contribute to risk of stroke.
The pathological changes of different subtypes of stroke are quite different (56) . Atherothrombotic stroke is mostly a disease of large arteries (.0.1 mm in diameter). ICH and lacunar infarction are primarily caused by small arteries as well as arteriole diseases. Genetic effects might differ between small and large vessel diseases, although so far the evidence is insufficient (57). Our results showed that the variant rs2507800 was associated with ICH and lacunar infarction, and not atherothrombotic stroke, indicating the variant might contribute to small vessel disease, rather than large vessel disease.
At present, no clear explanation is available for the aforementioned distinction. It could be due to differences in pathogenesis between small and large vessel diseases. It is plausible that small blood vessels are more vulnerable to endothelial dysfunction than large vessels; therefore, even subtle variations in the integrity of the vascular endothelium could affect the long-term risk of microvascular injury.
The function of miR-211 is largely unknown, although it has been reported to be expressed and upregulated in the injured carotid artery (58) and to be expressed in human cerebral arteries (our unpublished data). The association of miR-211 with risk of stroke through rs2507800 was consistent with the expression pattern of angiopoietin-1. However, the mechanism by which the binding of miR-211 can regulate the plasma levels of angiopoietin-1 is not fully understood and needs to be elucidated in the future. This is one limitation of the present study.
Another limitation of the present study is that the association between plasma or serum levels of angiopoietin-1 and development of stroke has not been well established. Previous studies showed that high serum angiopoietin-1 levels (angiopoietin-1 ≥35 ng/ml) are independently associated with good functional outcome of ICH (OR 14.7; 95% CI 3.6-60.0) (59) and the mice transfected with angiopoietin-1 expressing adenoviruses have high serum levels of angiopoietin-1, a reduction of BBB leakage in ischemic brain and consequently a decrease in ischemic lesion volume (48) . However, this evidence is not strong enough to draw the conclusion that plasma or serum levels of angiopoietin-1 are associated with development of stroke.
In conclusion, our results provide evidence that the T allele of rs2507800 in the 3 ′ -UTR of angiopoietin-1 might reduce the risk of stroke, probably by attenuating miR-211 binding, ameliorating the downregulation of angiopoietin-1, which would lead to the small vessels becoming vulnerable to damage and risk of stroke. This result might help to improve future prevention or therapy strategies for stroke.
MATERIALS AND METHODS
Human angiopoietin-1 3
′ -UTR luciferase constructs
To construct angiopoietin-1 3 ′ -UTR-luciferase reporter plasmids, a 48 bp sequence (Supplementary Material, Table S1 ) carrying either the wild type or the variant genotype of rs2507800 was synthesized and cloned into the pMIR-REPORT vector (Ambion, Austin, TX, USA), using restriction enzymes HindIII and SpeI. The reporter plasmid containing rs2507800A was defined as pMIR-A, and the one containing rs2507800T as pMIR-T. The resulting constructs (pMIR-A and pMIR-T) were verified by sequencing. The plasma levels of angiopoietin-1 were determined in 119 samples randomly selected from controls in the first study. To minimize the potential confounding effects, the subjects were recruited only when they also met the additional following criteria: (i) age at 35-65 years and (ii) without hypertension, as angiopoietin-1 plasma levels have been reported to be elevated in hypertensive patients (60, 61) . The variant rs2507800 was genotyped in all subjects. Of the subjects, 22 were homozygous for the T allele, 59 were heterozygous and 38 were homozygous for the A allele. The angiopoietin-1 concentrations were determined twice using a Quantikine Human Angiopoietin-1 Immunoassay kit (R&D, Minneapolis, MN, USA) according to the manufacturer's instructions.
Stroke sample population
The first case-control study comprised 438 stroke patients and 890 controls recruited from October 2004 to August 2005 in Xinyang city, Henan Province, China. Stroke was ascertained using strict neurological examination, computed tomography (CT) or magnetic resonance imaging (MRI) according to the International Classification of Diseases (9th Revision). Severe systemic diseases were excluded (such as collagenosis, inflammation, liver, neoplastic or renal diseases, endocrine and metabolic diseases, but not diabetes). Age-, sex-and residential area-matched controls were recruited from community-based healthy check-up individuals who were free of neurological diseases and cardiovascular as well as cerebrovascular diseases in addition to being subject to same exclusion criteria as the patients.
The second case-control study was the Multicenter Chinese Stroke Study, which has been described previously (62) . Briefly, 2000 consecutive stroke patients (age 35-74 years) and age-, sex-and residential area-matched controls were recruited from November 2000 to November 2001 from seven clinical centers (Yanzhou, Xian, Chongqing, Wuhan Xiehe, Wuhan Tongji, Beijing and Tianjin). We recruited three subtypes of stroke: cerebral thrombosis (thrombosis), lacunar infarction (lacunar) and ICH. The inclusion and exclusion criteria were identical to those used in the first study. Controls were selected simultaneously from the same demographic area as patients and matched for age (+5 years) and sex. Controls included 21.5% of patients with minor illnesses from the Departments of Ophthalmology, Gastroenterology, or Orthopedics, and 78.5% community-based inhabitants free of neurological disease. The controls were subject to the same exclusion criteria as the patients.
Before data analysis, 209 stroke patients and 157 controls were excluded due to indefinite diagnosis (24 patients) or insufficient DNA (185 patients and 202 controls). No significant differences were found in clinical characteristics between the included and excluded subjects. Finally, 1791 patients (mean + SD age, 60.4 + 9.5 years; 63.6% male) and 1843 controls (mean + SD age, 59.7 + 8.3 years; 57.6% male) were eligible for the genetic analysis.
Both studies were approved by the local ethics committees of the collaborating hospitals. All participants reported themselves as Han nationality and provided written informed consent.
Biochemical variable determination and clinical data collection
Blood samples were collected after a 12 h overnight fast. In acute medical events, blood collection was delayed for at least 6 weeks. Plasma and buffy coat cells were separated by centrifugation, and kept at 2708C. Biochemical variables, including blood glucose, total cholesterol, triglycerides and high-density lipoprotein cholesterol (HDL-C), were determined using an automatic analyzer (Hitachi 7060, Tokyo, Japan) within 3 months of the first episode of stroke. All measurements were taken in a laboratory at the FuWai hospital qualified by the Centers for Disease Control and Prevention (CDC).
Gene variant selection and genotyping
The variant rs2507800 (+3379A/T) was selected based on its relevance to gene expression, being located in the miR-211 target site of the 3 ′ -UTR of angiopoietin-1. Genomic DNA was isolated from white blood cell buffy coat cells as described previously (63) . The variant rs2507800 was genotyped by a ligase detection reaction (LDR) by the Shanghai Biowing Applied Biotechnology Co., Ltd. The primer and probe sequences and PCR and LDR product lengths of the variant are summarized in Supplementary Material, Table S2 . Fragment amplification was carried out in 20 ml of multiplex PCR mixture containing 50 ng (1 ml) of genomic DNA, 2 ml of 1× buffer, 0.6 ml of Mg 2+ , 2 ml of dNTPs, 0.2 ml of Taq polymerase, 4 ml of 1× Q-solution, 0.4 ml of primer mix and 9.8 ml of ddH 2 O. The PCR included initial denaturing at 958C for 15 min, followed by 35 cycles of denaturing at 948C for 30 s, annealing at 598C for 1 min, and extension at 728C for 1 min. The reaction was completed by a final extension at 728C for 7 min. Reactions were performed on a thermal cycler Gene Amp PCR system 9600 (Perkin Elmer, Waltham, MA, USA). Further amplification was performed in a 10 ml volume of multiplex LDR reaction mixture, containing 1 ml (100 ng) of the resultant probe mix, 1 ml of probe mix, 0.05 ml NEB Taq DNA ligase and 6.95 ml of ddH 2 O. The LDR conditions included initial denaturing at 958C for 2 min, followed by 35 cycles of denaturing at 948C for 30 s and annealing at 508C for 2 min. LDR products (1 ml) were mixed with 1 ml of ROX (ABI, Foster City, CA, USA) and 1 ml of loading buffer, detected in an ABI PRISM 377 DNA Sequencer, and analyzed with Genemapper (ABI, Foster City, CA, USA). Reproducibility of genotyping was confirmed by sequencing in 400 randomly selected samples with 100% concordance.
Statistical analysis
A x
2 test was used to test for qualitative variables, genotype/ allele frequencies and for the HWE of the variant. Differences of quantitative variables between groups were analyzed using the Student t-test. The levels of plasma triglycerides (TG) were highly skewed; therefore, the Mann -Whitney U test was used to examine differences in TG levels between groups. The associations between the variant and stroke and its subtypes were detected using unconditional logistic regression models. The covariates for the logistic regression models included conventional risk factors, as follows: age, gender, clinic centers, body mass index, triglycerides, total cholesterol, HDL cholesterol, blood glucose, blood pressure, smoking, alcohol intake, history of hypertension and DM. One-way ANOVA was used to compare the relative luciferase activities of the angiopoietin-1 gene 3 ′ -UTR containing either rs2507800A or rs2507800T. The distribution of angiopoinetin-1 plasma levels is skewed non-normally, so the Kruskal-Wallis test was used to compare the plasma angiopoietin-1 levels among subjects carrying different genotypes of variant rs2507800. The population-attributable fraction was estimated for variants using the following equation: population-attributable fraction (%) ¼ 100 × p(OR 2 1)/[p (OR 2 1) + 1], where p is the frequency of the at-risk genotypes among control subjects. All statistics were performed with the SPSS 13.0 package. A value of P , 0.05 was taken as significant (two tailed).
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